Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

SCRI Development Innovations

Status: Completed

Conditions: Non Small Cell Lung Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01522833

SCRI OUTCOMES 13

Details and patient eligibility

About

With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.

Enrollment: 27 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients must have had NSCLC.
• Patients must have received erlotinib (single-agent) for six months or longer for NSCLC in the second/third line setting or as maintenance therapy.
• Patients must have tissue available for EGFR-mutation status testing (if not previously performed) or EGFR-mutation status test results available.
• Patients must have tissue available for exploratory genetic analysis.
• Patients must have all clinical information, treatment response data and outcomes data available for review.
• Patients must be deceased.

Trial design

27 participants in 2 patient groups

Cohort A

Description:

EGFR Wild Type patients

Cohort B

Description:

EGFR mutation patients